[{"Assets_0_Q3_USD":219954000.0,"CommonStockSharesOutstanding_0_Q3_shares":64503326.0,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":-27630000.0,"NetIncomeLoss_1_Q3_USD":-16782000.0,"NetIncomeLoss_3_Q3_USD":-50571000.0,"StockholdersEquity_0_Q3_USD":173929000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q3_USD":1026000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_3_Q3_USD":3079000.0,"Ticker":"FATE","CIK":"1434316","name":"FATE THERAPEUTICS INC","OfficialName":"Fate Therapeutics Inc. Common Stock","form":"10-Q","period":"20180930","fy":"2018.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"3545646272.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Biological Products (No Diagnostic Substances)","Market":"NASDAQ","SP500":"nan","filed":"20181101"}]